UK gets closer to formulating wider societal benefit pricing mechanism
This article was originally published in Scrip
Executive Summary
The UK is getting closer to coming up with a way to link the price of a new drug to the benefits it offers, not only to patients, but crucially to wider society. Although some pricing and reimbursement authorities look at a drug's wider societal benefits, no one has yet come up with a way of concretely linking them to a drug's price. So if the UK gets this right, whatever it comes up with could have a big impact in many other cash-strapped markets wrestling with limited drugs budgets and soaring medicine costs.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.